Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

MJ Gleeson profits sink 17% after 'challenging year'

(Sharecast News) - Housebuilder MJ Gleeson has reported a sharp fall in annual earnings despite an increase in revenues as higher incentives weighed on profit margins - though the company reiterated targets to treble profitability in the medium term. Revenues were up 5.9% at £265.8m over the 12 months to 30 June, with the number of homes sold rising to 1,793 from 1,772.

However, with underlying selling prices rising by just 0.6% and the gross profit on homes sold dropping to 20.7% from 24.1%, pre-tax profit fell 17.3% to £20.5m.

"This year has been challenging for Gleeson, and despite selling more homes relative to FY2024, there have been factors which stalled our momentum," said chief executive Graham Prothero.

"Market demand has been steady, and we have maintained a robust sales rate, reflected in our net open market reservations rate, up 28% in the second half against the same period last year. Selling prices, however, remained constrained, with incentives continuing at an elevated level, restricting material margin improvement."

The company declared a final dividend of 7p per share, taking the total annual payout to 11p - covered 2.6 times by normalised earnings and in line with last year.

Since the financial year-end, the company said it has seen an improvement in open-market net reservation rates in a "stable market", and highlighted the strong land pipeline of 19,638 plots at the end of June, up 500 over the year.

Looking further ahead, MJ Gleeson reaffirmed its medium-term objective of delivering 3,000 new homes per annum - a target that is estimated to see profit before tax "broadly triple".

"With a number of sites close to achieving planning and others in sale processes, Gleeson Land is well placed to deliver another robust performance in FY2026 and is strongly positioned for significant growth from FY2027," the company said.

Shares were up 2.8% at 350.47p by 0950 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.